SCHEMBL9922201

SCHEMBL9922201

O=C(Nc1ccc(-n2ccc3cc4[nH]cnc4cc3c2=O)c(F)c1)NS(=O)(=O)c1cccs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.38
MEN1 O00255 7/20 0.38
MAPT P10636 4/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 2/20 0.38
BLM P54132 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MCL1 Q07820 1/20 0.38
KDR P35968 2/20 0.36
EPHB4 P54760 2/20 0.36
TEK Q02763 2/20 0.36
EGFR P00533 1/20 0.36
PDGFRB P09619 1/20 0.36
KIT P10721 1/20 0.36
FGFR1 P11362 1/20 0.36
FLT1 P17948 1/20 0.36
LMNA P02545 3/20 0.36
P2RY12 Q9H244 1/20 0.33
IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922212 0.97 KMT2A (0.36) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL13182767 0.87 P2RY12 (0.39) KMT2AMEN1POLBKDREPHB4
SCHEMBL9922077 0.87 P2RY12 (0.47) KMT2AMEN1MAPTALDH1A1BLM
SCHEMBL9922200 0.85 KMT2A (0.37) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL9922815 0.84 P2RY12 (0.47) KMT2AMEN1MAPTPOLBKDR
SCHEMBL14113533 0.84 P2RY12 (0.39) KMT2AMEN1POLBKDREPHB4
SCHEMBL9922206 0.81 KMT2A (0.39) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL12161004 0.79 P2RY12 (0.43) KMT2AMEN1MAPTALDH1A1EPHB4
SCHEMBL9922642 0.78 P2RY12 (0.34) POLBKDREPHB4TEKEGFR
SCHEMBL12177235 0.78 P2RY12 (0.37) MAPTPOLBKDREPHB4TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 KMT2A 3009/4885MEN1 4498/4885MAPT 4832/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 KMT2A 3023/4885MEN1 4499/4885MAPT 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.